LOAMS
KNSA icon

Lombard Odier Asset Management (Switzerland)’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Lombard Odier Asset Management (Switzerland)’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-116,376
Closed -$1.25M – 272
2023
Q1 		$1.25M Buy
116,376
+57,544
+98% +$758K 0.11% 162
2022
Q4 		$881K Buy
+58,832
New +$857K 0.07% 193

Other funds holding KNSA

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Lombard Odier Asset Management (Switzerland)'s KNSA Position: Q2 2023 in Review

Lombard Odier Asset Management (Switzerland) sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2023, closing a stake of 116,376 shares — an estimated $1.25M sold.

Lombard Odier Asset Management (Switzerland) first reported a position in KNSA in Q4 2022 and held it in 2 quarters. The position peaked at $1.25M in Q1 2023. 127 funds tracked by Wall St. Rank hold KNSA as of Q2 2023.

  • Lombard Odier Asset Management (Switzerland) reported no remaining Kiniksa Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Lombard Odier Asset Management (Switzerland) sold 116,376 Kiniksa Pharmaceuticals shares in Q2 2023, an estimated $1.25M.
  • Lombard Odier Asset Management (Switzerland) first reported a position in Kiniksa Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Lombard Odier Asset Management (Switzerland)'s Kiniksa Pharmaceuticals position peaked at $1.25M in Q1 2023.
  • 127 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2023.

Based on Lombard Odier Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 14 Aug 2023.